GlassScriptPhysician profile
Keith C Kappel
NPI 1851395537
$3,893.23
in general payments reported to CMS, 2019-2025
24 companies · $713 in 2025
The $713 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $304 · 2021: $665 · 2022: $402 · 2023: $640 · 2024: $554 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,907.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $1,006.44 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $615.79 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $305.51 | 2019-2025 | |
| Glaxosmithkline, LLC. | $297.91 | 2020-2025 | Bexsero, Menveo, Penmenvy |
| Corium, LLC | $283.88 | 2021-2025 | Azstarys |
| Tris Pharma INC | $260.74 | 2019-2025 | Onyda Xr |
| Adlon Therapeutics L.P. | $172.41 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $171.37 | 2020-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Collegium Pharmaceutical, INC. | $136.24 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $89.32 | 2019-2025 | Relexxii |
| Takeda Pharmaceuticals U.S.A., INC. | $81.51 | 2019-2021 | |
| Neos Therapeutics, LP | $77.78 | 2019-2021 | |
| Phadia US INC. | $73.31 | 2019-2025 | Immunocap |
| Sanofi-Aventis U.S. LLC | $56.65 | 2024-2025 | |
| Rhodes Pharmaceuticals L.P. | $53.79 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $51.17 | 2019-2020 | |
| Sanofi Pasteur INC. | $30.53 | 2023-2025 | |
| Cranial Technologies, INC | $28.44 | 2024-2025 | Doc Band |
| Seqirus USA INC | $21.63 | 2025 | Flucelvax |
| Millicent US INC | $20.29 | 2025 | Intrarosa, Femlyv |
| Ars Pharmaceuticals Operations, INC. | $17.67 | 2025 | Neffy |
| Kowa Pharmaceuticals America, INC. | $14.69 | 2025 | Zoryve |
| Azurity Pharmaceuticals, INC. | $14.09 | 2025 | Alvesco |
| Novartis Pharmaceuticals Corporation | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Kappel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.